Company intelligence / Profile preview

Circulogene

Birmingham, Alabama, United Statescirculogene.com ↗

Ownership: Private
Employees: ~45
Development stage: Commercial

Overview

Circulogene provides proprietary liquid biopsy services using next-generation sequencing and PCR to deliver comprehensive molecular profiling of cancer from a single tube of blood within one week. Their technology enables detection of actionable biomarkers in both somatic and germline DNA/RNA, supporting personalized therapy selection, efficacy monitoring, and recurrence surveillance. Over 25,000 patients have been served since inception.

Therapeutic areas: Oncology
Modalities: Diagnostic test (liquid biopsy)Next-generation sequencing (NGS)Polymerase chain reaction (PCR)
Industry: Molecular Diagnostics

Drug pipeline

3 assets

TumorClear

Commercial

Indications: Cancer

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Circulogene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Circulogene.

Explore the full profile